Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy

References

• Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted Life-Years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1357–1768.
   Web of Science ®Google Scholar
• Wong MCS, Lao XQ, Ho KF, et al. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300.
   PubMedGoogle Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Froudarakis ME. Pleural effusion in lung cancer: more questions than answers. Respiration. 2012;83(5):367–376.
   PubMed Web of Science ®Google Scholar
• Economidou F, Margantopoulos G, Antoniou KM, et al. The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications. Exp Ther Med. 2010;1(1):3–7.
   PubMed Web of Science ®Google Scholar
• Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 1999;5(11):3364–3368.
   PubMed Web of Science ®Google Scholar
• Wang M, Zeng Q, Li Y, et al. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo. J Drug Target. 2020;28(9):961–969.
   PubMed Web of Science ®Google Scholar
• Qin W, Liu B, Yi M, et al. Antifibrotic agent pirfenidone protects against development of Radiation-Induced pulmonary fibrosis in a murine model. Radiat Res. 2018;190(4):396–403.
   PubMed Web of Science ®Google Scholar
• E R, C A, J A, et al. Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung. 2005;183(3):185–195.
   PubMed Web of Science ®Google Scholar
• M B, A M, T P. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013;15(3):207–216.
   PubMed Web of Science ®Google Scholar
• Roviello G, Ravelli A, Polom K, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372(2):187–191.
   PubMed Web of Science ®Google Scholar
• Tao H, Meng Q, Li M, et al. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion. Thorac Cancer. 2018;9(2):298–304.
   PubMed Web of Science ®Google Scholar
• Sabang RL, Ganghiraj D, Fanucchi M, et al. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med. 2018;12(2):87–94.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747–758.
   PubMed Web of Science ®Google Scholar
• King M, Sensakovic WF, Maxim P, et al. Line-Enhanced deformable registration of pulmonary computed tomography images before and after radiation therapy with Radiation-Induced fibrosis. Technol Cancer Res Treat. 2018;17:153303461774941. 1533034617749419.
   Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219–3225.
   PubMed Web of Science ®Google Scholar
• Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36(1):109–140.
   PubMed Web of Science ®Google Scholar
• Li N, Wang Z, Yuan G, et al. An oral small molecule VEGFR2 inhibitor, apatinib, in patients with recurrent or refractory cervical cancer: a real world study. J Oncol. 2020;2020:3852373.
   PubMed Web of Science ®Google Scholar
• Shao F, Zhang H, Yang X, et al. Adverse events and management of apatinib in patients with advanced or metastatic cancers: a review. Neoplasma. 2020;67(4):715–723.
   PubMed Web of Science ®Google Scholar
• Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137–4147.
   PubMed Web of Science ®Google Scholar
• Fathi Maroufi N, Rashidi MR, Vahedian V, et al. Therapeutic potentials of apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sci. 2020;241:117106.
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006;66(18):9134–9142.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis E. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and Pro-Angiogenic therapies. Genes & Cancer. 2011;2(12):1097–1105.
   PubMedGoogle Scholar
• Verheul HM, Hoekman K, Jornal AS, et al. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(S1):45–50.
   Google Scholar
• Verheul HM, Hoekman K, Jorna AS, et al. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(S1):45–50.
   PubMedGoogle Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol. 2007;25(12):1539–1544.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Talento S, Mitra N, et al. Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous Non-Small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5):469–477.
   PubMed Web of Science ®Google Scholar
• Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a Meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(33):e11936.
   PubMed Web of Science ®Google Scholar
• Bai ZG, Zhang ZT. A systematic review and Meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. OTT. 2018;11:7077–7087.
   Web of Science ®Google Scholar
• Xu MD, Liu L, Wu MY, et al. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Oncogenesis. 2018;7(11):94.
   PubMed Web of Science ®Google Scholar
• N D, X L, F L, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion. Oncol Rep. 2013;29(6):2332–2340.
   PubMed Web of Science ®Google Scholar
• J L, L P, G Z, et al. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res. 2016;36(3):1313–1318.
   PubMed Web of Science ®Google Scholar
• Acencio M, Puka J, Alvarenga VA, et al. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion. Oncotarget. 2017;8(62):105093–105102.
   PubMedGoogle Scholar
• Liu W, Xu J, Wang M, et al. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol. 2011;39(5):1213–1220.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e341S–e368S.
   PubMed Web of Science ®Google Scholar
• Alan S, Robert G, al P. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Zhou YJ, Ding RL, et al. In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells. PLoS One. 2018;13(7):e0200845.
   PubMed Web of Science ®Google Scholar
• Tissot C, Gay P, Brun C, et al. Novel insights into the systemic treatment of lung cancer malignant pleural effusion. Clin Respir J. 2019;13(3):131–138.
   PubMed Web of Science ®Google Scholar
• Acencio MM, Puka J, Marchi E, et al. A modified experimental model of malignant pleural disease induced by lung lewis carcinoma (LLC) cells. J Transl Med. 2015;13:302.
   PubMed Web of Science ®Google Scholar
• Ma X, Sun Y, Wang S, et al. Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein. Transl Lung Cancer Res. 2012;1(3):170–178.
   PubMedGoogle Scholar
• Xie SL, Yang MH, Chen K, et al. Efficacy of arsenic trioxide in the treatment of malignant pleural effusion caused by pleural metastasis of lung cancer. Cell Biochem Biophys. 2015;71(3):1325–1333.
   PubMed Web of Science ®Google Scholar
• Nie K, Zhang Z, You Y, et al. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer. Thorac Cancer. 2020;11(1):8–14.
   PubMed Web of Science ®Google Scholar
• Lee KH, Ko BH, Paik JY, et al. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med. 2005;46(9):1531–1536.
   PubMed Web of Science ®Google Scholar
• Xie F, Ding RL, He WF, et al. In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma. Drug Deliv. 2017;24(1):1410–1418.
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.
   PubMed Web of Science ®Google Scholar
• van der Leest C, Smit EF, Baas J, et al. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer? Lung Cancer. 2012;76(1):67–71.
   PubMed Web of Science ®Google Scholar
• Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10):1618.[
   PubMed Web of Science ®Google Scholar
• Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157(6):1893–1903.
   PubMed Web of Science ®Google Scholar
• Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009;15(4):380–387.
   PubMed Web of Science ®Google Scholar
• Mallow C, Hayes M, Semaan R, et al. Minimally invasive palliative interventions in advanced lung cancer. Expert Rev Respir Med. 2018;12(7):605–614.
   PubMed Web of Science ®Google Scholar
• Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8(4):294–301.
   PubMed Web of Science ®Google Scholar
• Fafliora E, Hatzoglou C, Gourgoulianis KI, et al. Systematic review and Meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. Physiol Rep. 2016;4(24):e12978.
   PubMedGoogle Scholar
• Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17(10):611–625.
   PubMed Web of Science ®Google Scholar
• Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor, the. Journal of Biological Chemistry. 1994;269(43):26988–26995.
   PubMed Web of Science ®Google Scholar
• Mori R, Fujimoto D, Ito M, et al. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget. 2017;8(29):48521–48524.
   PubMedGoogle Scholar
• Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6(3):957–965.
   PubMed Web of Science ®Google Scholar
• Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer. 2011;104(8):1270–1277.
   PubMed Web of Science ®Google Scholar
• Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8(1):15–27.
   PubMedGoogle Scholar
• Qiu H, Li J, Liu Q, et al. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with paclitaxel. Cell Cycle. 2018;17(10):1235–1244.
   PubMed Web of Science ®Google Scholar
• Inoue S, Hartman A, Branch CD, et al. Mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007;15(2):287–294.
   PubMed Web of Science ®Google Scholar
• Bao X, Wang M-W, Luo J-M, et al. Optimization of early response monitoring and prediction of cancer antiangiogenesis therapy via noninvasive PET molecular imaging strategies of multifactorial bioparameters. Theranostics. 2016;6(12):2084–2098.
   PubMed Web of Science ®Google Scholar
• Goggi JL, Bejot R, Moonshi SS, et al. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. J Nucl Med. 2013;54(9):1630–1636.
   PubMed Web of Science ®Google Scholar
• AD V. The lessons of GIST–PET and PET/CT: a new paradigm for imaging, The oncologist null(undefined) 2008. 8–13.
   Google Scholar
• Sun Y, Yu H, Ma J, et al. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS One. 2016;11(8):e0161764.
   PubMed Web of Science ®Google Scholar
• Nakajima R, Abe K, Sakai S. Diagnostic ability of FDG-PET/CT in the detection of malignant pleural effusion. Medicine (Baltimore. 2015;94(29):e1010. )
   PubMed Web of Science ®Google Scholar
• C G, L.-F N, T M, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Molecular Cancer Therapeutics. 2014;13(1):165–178.
   PubMed Web of Science ®Google Scholar
• Collet G, Lamerant-Fayel N, Tertil M, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther. 2014;13(1):165–178.
   PubMed Web of Science ®Google Scholar
• Xu W, Puligandla M, Manola J, et al. Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma. Clin Cancer Res. 2019;25(20):6098–6106.
   Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.
   PubMed Web of Science ®Google Scholar
• Henriet P, Emonard H. Matrix metalloproteinase-2: Not (just) a "hero" of the past. Biochimie. 2019;166:223–232.
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 2012;114:237–267.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:4–10.
   PubMed Web of Science ®Google Scholar
• Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2(7):a006502.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and Pro-Angiogenic therapies. Genes Cancer. 2011;2(12):1097–1105.
   PubMedGoogle Scholar
• Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis. 2017;20(2):185–204.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen Y, Li F, et al. Atezolizumab and bevacizumab attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing Epithelial-Mesenchymal transition. Front Immunol. 2019;10:867.
   PubMed Web of Science ®Google Scholar
• Gao X, McDermott DF. Combinations of bevacizumab with immune checkpoint inhibitors in renal cell carcinoma. Cancer J. 2018;24(4):171–179.
   PubMed Web of Science ®Google Scholar
• Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018;9(2):115.
   PubMed Web of Science ®Google Scholar